Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hemab Therapeutics
Biotech
Hemab CEO seeks ‘flavor of a multi-product coagulation company’
With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
Will Maddox
Aug 13, 2026 9:00am
Seaport CEO's 'rationale behind going public' via $255M IPO
May 1, 2026 12:30pm
Seaport, Hemab chart courses for $180M IPOs this week
Apr 27, 2026 12:29pm
Seaport, Hemab prepare IPOs to fund depression, clotting drugs
Apr 13, 2026 7:12am
Hemab raises $157M series C for rare bleeding disorder goals
Oct 27, 2025 6:00am
Merck KGaA lands new R&D chief—Chutes & Ladders
Sep 5, 2025 8:30am
